Work

Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study

Year: 2016

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2016.01.022

Authors: Pasi A. Jänne, Alice T. Shaw, D. Ross Camidge, Giuseppe Giaccone, S. Martin Shreeve, Yiyun Tang, Zelanna Goldberg, Jean-François Martini, Huiping Xu, Leonard P. James, Benjamin J. Solomon

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital, University of Colorado Denver, Georgetown University, Pfizer (United States), Peter MacCallum Cancer Centre

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Ariad Pharmaceuticals, Daiichi-Sankyo, Astellas Pharma, Genentech, Chugai Pharmaceutical, Ignyta

OpenAlex ID: W2285453897

FWCI: 7.675

Cites: 47

Cited by: 57

Related to: 10